Organ transplantation and vaccination

Chen Song; Zhang Weijie

doi:10.3969/j.issn.1674-7445.2022.01.002

Volume 13 Issue 1

Jan. 2022

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2022 > 13(1): 6-11

Chen Song, Zhang Weijie. Organ transplantation and vaccination[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 6-11. doi: 10.3969/j.issn.1674-7445.2022.01.002

Citation:

Chen Song, Zhang Weijie. Organ transplantation and vaccination[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 6-11. doi: 10.3969/j.issn.1674-7445.2022.01.002

Citation:

Chen Song, Zhang Weijie. Organ transplantation and vaccination[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 6-11. doi: 10.3969/j.issn.1674-7445.2022.01.002

PDF( 995 KB)

Organ transplantation and vaccination

doi: 10.3969/j.issn.1674-7445.2022.01.002

Chen Song,
Zhang Weijie^,

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation of Ministry of Education, Key Laboratory of Organ Transplantation of National Health Commission of China, Key Laboratory of Organ Transplantation of Chinese Academy of Medical Sciences, Wuhan 430030, China

More Information

Corresponding author: Zhang Weijie, E-mail: wjzhangtj@126.com
Received Date: 2021-10-08
Available Online: 2022-01-12
Publish Date: 2022-01-15

Abstract

Abstract

Organ transplant recipients are at a high risk of infection with high hospitalization rate, critical rate and fatality, due to low immune function caused by taking immunosuppressants for a period of long time after organ transplantation. Currently, vaccination is recognized as an effective approach to prevent infection. Organ transplant recipients may be vaccinated according to individual conditions. However, the sensitivity to vaccines may decline in organ transplant recipients. The types, methods and timing of vaccination have constantly been the hot spots of clinical trials. In this article, the general principles, specific vaccines and SARS-CoV-2 vaccines of vaccination in organ transplant recipients were briefly reviewed, aiming to provide reference for the vaccination of organ transplant recipients. Moreover, current status of SARS-CoV-2 vaccination for organ transplant recipients was illustrated under the global outbreak of novel coronavirus pneumonia pandemic.
- Organ transplantation,
- Influenza vaccine,
- Pneumococcal vaccine,
- Hepatitis B vaccine,
- Hepatitis A vaccine,
- Rabies vaccine,
- Tetanus vaccine,
- Human papillomavirus vaccine,
- SARS-CoV-2 vaccine

FullText(HTML)

References(38)

References

[1]	MOMBELLI M, KAMPOURI E, MANUEL O. Influenza in solid organ transplant recipients: epidemiology, management, and outcomes[J]. Expert Rev Anti Infect Ther, 2020, 18(2): 103-112. DOI: 10.1080/14787210.2020.1713098.
[2]	MARINELLI TM, KUMAR D. Influenza virus infection and transplantation[J]. Transplantation, 2021, 105(5): 968-978. DOI: 10.1097/TP.0000000000003486.
[3]	Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York[J]. J Am Soc Nephrol, 2020, 31(6): 1150-1156. DOI: 10.1681/ASN.2020030375.
[4]	AKALIN E, AZZI Y, BARTASH R, et al. COVID-19 and kidney transplantation[J]. N Engl J Med, 2020, 382(25): 2475-2477. DOI: 10.1056/NEJMc2011117.
[5]	KENNEDY J. Vaccine hesitancy: a growing concern[J]. Paediatr Drugs, 2020, 22(2): 105-111. DOI: 10.1007/s40272-020-00385-4.
[6]	DANZIGER-ISAKOV L, KUMAR D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13563. DOI: 10.1111/ctr.13563.
[7]	徐胜勇, 张秋彬, 李克莉, 等. 疫苗接种不良事件紧急处理中国急诊专家共识[J]. 中国急救医学, 2021, 41(2): 93-100. XU SY, ZHANG QB, LI KL, et al. Consensus of Chinese emergency experts on emergency management of vaccination adverse events[J]. Chin J Crit Care, 2021, 41(2): 93-100.
[8]	Guidelines for vaccination of solid organ transplant candidates and recipients[J]. Am J Transplant, 2004, 4(Suppl 10): 160-163. DOI: 10.1111/j.1600-6135.2004.00737.x.
[9]	AVERY RK, MICHAELS M. Update on immunizations in solid organ transplant recipients: what clinicians need to know[J]. Am J Transplant, 2008, 8(1): 9-14. DOI: 10.1111/j.1600-6143.2007.02051.x.
[10]	RUBIN LG, LEVIN MJ, LJUNGMAN P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host[J]. Clin Infect Dis, 2014, 58(3): 309-318. DOI: 10.1093/cid/cit816.
[11]	KUMAR D, FERREIRA VH, BLUMBERG E, et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients[J]. Clin Infect Dis, 2018, 67(9): 1322-1329. DOI: 10.1093/cid/ciy294.
[12]	国家免疫规划技术工作组流感疫苗工作组. 中国流感疫苗预防接种技术指南(2020-2021)[J]. 中华流行病学杂志, 2020, 41(10): 1555-1576. DOI: 10.3760/cma.j.cn112338-20200904-01126. Influenza Vaccine Working Group of National Immunization Program Technical Working Group. Technical guidelines for seasonal influenza vaccination in China (2020-2021)[J]. Chin J Epidemiol, 2020, 41(10): 1555-1576. DOI: 10.3760/cma.j.cn112338-20200904-01126.
[13]	DENDLE C, STUART RL, MULLEY WR, et al. Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence[J]. Vaccine, 2018, 36(42): 6253-6261. DOI: 10.1016/j.vaccine.2018.08.069.
[14]	ERIKSSON M, KÄYHTY H, SAHA H, et al. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients[J]. Transpl Infect Dis, 2020, 22(4): e13343. DOI: 10.1111/tid.13343.
[15]	中华预防医学会, 中华预防医学会疫苗与免疫分会. 肺炎球菌性疾病免疫预防专家共识(2020版)[J]. 中华流行病学杂志, 2020, 41(12): 1945-1979. DOI: 10.3760/cma.j.cn112338-20201111-01322. Chinese Preventive Medicine Association, Vaccine and Immunology Branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version)[J]. Chin J Epidemiol, 2020, 41(12): 1945-1979. DOI: 10.3760/cma.j.cn112338-20201111-01322.
[16]	MILLER-HANDLEY H, PAULSEN G, HOOPER DK, et al. Durability of the hepatitis B vaccination in pediatric renal transplant recipients[J]. Clin Transplant, 2018, 32(5): e13247. DOI: 10.1111/ctr.13247.
[17]	MOAL V, MOTTE A, VACHER-COPONAT H, et al. Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation[J]. J Clin Virol, 2015, 68: 32-36. DOI: 10.1016/j.jcv.2015.04.011.
[18]	WATKINS SL, ALEXANDER SR, BREWER ED, et al. Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure[J]. Am J Kidney Dis, 2002, 40(2): 365-372. DOI: 10.1053/ajkd.2002.34521.
[19]	GÜNTHER M, STARK K, NEUHAUS R, et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients[J]. Transplantation, 2001, 71(3): 477-479. DOI: 10.1097/00007890-200102150-00023.
[20]	中国疾病预防控制中心. 狂犬病预防控制技术指南(2016版)[J]. 中国病毒病杂志, 2016, 6(3): 161-188. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201603001.htm Chinese Center for Disease Control and Prevention. Technical guidelines for human rabies prevention and control (2016 edition)[J]. Chin J Viral Dis, 2016, 6(3): 161-188. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201603001.htm
[21]	王传林, 刘斯, 邵祝军, 等. 外伤后破伤风疫苗和被动免疫制剂使用指南[J]. 中国疫苗和免疫, 2020, 26(1): 111-115, 127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202001023.htm WANG CL, LIU S, SHAO ZJ, et al. Guidelines for post-traumatic use of tetanus vaccines and passive immune preparations[J]. Chin J Vaccin Immun, 2020, 26(1): 111-115, 127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202001023.htm
[22]	LARSEN HK, THOMSEN LT, HAEDERSDAL M, et al. Risk of genital warts in renal transplant recipients-a registry-based, prospective cohort study[J]. Am J Transplant, 2019, 19(1): 156-165. DOI: 10.1111/ajt.15056.
[23]	AZZI Y, BARTASH R, SCALEA J, et al. COVID-19 and solid organ transplantation: a review article[J]. Transplantation, 2021, 105(1): 37-55. DOI: 10.1097/TP.0000000000003523.
[24]	NASRALLAH MM, OSMAN NA, ELALFY M, et al. Transplantation in the era of the COVID-19 pandemic: how should transplant patients and programs be handled?[J]. Rev Med Virol, 2021, 31(1): 1-9. DOI: 10.1002/rmv.2149.
[25]	RAJA MA, MENDOZA MA, VILLAVICENCIO A, et al. COVID-19 in solid organ transplant recipients: a systematic review and Meta-analysis of current literature[J]. Transplant Rev (Orlando), 2021, 35(1): 100588. DOI: 10.1016/j.trre.2020.100588.
[26]	TID COVID-19 guidance focused review: SARS-CoV-2 vaccines in transplant recipients[EB/OL]. [2021-09-30]. https://tts.org/26-tid/tid-resources/850-tid-covid-19-guidance-focused-review-sars-cov-2-vaccines-in-transplant-recipients.
[27]	BOYARSKY BJ, WERBEL WA, AVERY RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients[J]. JAMA, 2021, 325(17): 1784-1786. DOI: 10.1001/jama.2021.4385.
[28]	BENOTMANE I, GAUTIER-VARGAS G, COGNARD N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine[J]. Kidney Int, 2021, 99(6): 1498-1500. DOI: 10.1016/j.kint.2021.04.005.
[29]	KAMAR N, ABRAVANEL F, MARION O, et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients[J]. N Engl J Med, 2021, 385(7): 661-662. DOI: 10.1056/NEJMc2108861.
[30]	ALEJO JL, MITCHELL J, CHIANG TP, et al. Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series[J]. Transplantation, 2021, 105(12): e280-e281. DOI: 10.1097/TP.0000000000003934.
[31]	BOYARSKY BJ, OU MT, GREENBERG RS, et al. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients[J]. Transplantation, 2021, 105(5): e56-e57. DOI: 10.1097/TP.0000000000003654.
[32]	OU MT, BOYARSKY BJ, CHIANG TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept[J]. Transplantation, 2021, 105(9): 2119-2123. DOI: 10.1097/TP.0000000000003824.
[33]	OU MT, BOYARSKY BJ, MOTTER JD, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients[J]. Transplantation, 2021, 105(10): 2170-2174. DOI: 10.1097/TP.0000000000003780.
[34]	AL KAABI N, ZHANG Y, XIA S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial[J]. JAMA, 2021, 326(1): 35-45. DOI: 10.1001/jama.2021.8565.
[35]	JARA A, UNDURRAGA EA, GONZÁLEZ C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile[J]. N Engl J Med, 2021, 385(10): 875-884. DOI: 10.1056/NEJMoa2107715.
[36]	疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[EB/OL]. [2021-09-30]. http://www.nhc.gov.cn/jkj/s3582/202103/c2febfd04fc5498f916b1be080905771.shtml.
[37]	Centers for disease control and prevention[EB/OL]. [2021-09-30]. https://www.cdc.gov/DataStatistics/.
[38]	ESOT congress 2021[EB/OL]. [2021-09-30]. https://www.esotcongress.org/.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (716) PDF downloads(160)

Organ transplantation and vaccination

doi: 10.3969/j.issn.1674-7445.2022.01.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Organ transplantation and vaccination

doi: 10.3969/j.issn.1674-7445.2022.01.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content